Next-generation coronavirus vaccine trials to begin soon - University of the Sunshine Coast, Queensland, Australia

Accessibility links

Next-generation coronavirus vaccine trials to begin soon

23 Aug 2021

Clinical trials will soon begin on a possible next-generation COVID-19 vaccine that is hoped to provide better protection against the SARS-CoV-2 coronavirus.

USC Clinical Trials will be the first location globally to trial this new potential COVID-19 vaccine, produced by American company Icosavax, in healthy participants on the Sunshine Coast and just north of Brisbane.

The study will be assessing the new potential vaccine’s safety and ability to generate good immune responses in two groups of volunteers.

The first group will involve participants who have not had COVID-19 or received a COVID vaccine, while the second group will require participants who have completed a full course of COVID-19 vaccination.

USC Clinical Trial’s Principal Investigator Dr Rob Scott will oversee the clinical trial, which aims to identify the optimal dose and safety of this virus-like particle (VLP) vaccine that has been produced using nanoparticle technology.

“Virus-like particles display multiple copies of the protective antigens in a manner that closely resembles viruses but contain no genetic material,” Dr Scott said.

“Licensed VLP vaccines are well known to induce a robust and durable immune response. This type of vaccine can also be redirected towards new coronavirus strains as they emerge.”

USC Clinical Trials Director Lucas Litewka said the need for new and continuing research into potential COVID-19 vaccines was fundamental to improving our pandemic response and preparedness.

“We hope to build upon our experience in COVID-19 vaccine clinical trials to partner on this new and innovative vaccine technology,” he said.

The study, to be conducted at USC Clinical Trials’ Sippy Downs and Health Hub Morayfield clinics, requires healthy participants aged 18 to 69.

The trial is open to those who are vaccinated and unvaccinated against COVID-19 and requires that participants attend about eight clinic visits and answer three phone calls over a seven-month period.

Participants will be reimbursed for their time and travel costs related to the study.

Those interested in participating can find more information at the USC Clinical Trials webpage.

Related articles

clinical trials
Clinical trial of potential treatments for abnormal blood lipid levels
14 Dec 2021

USC Clinical Trials is partnering with Arrowhead Pharmaceuticals to assess potential new treatments for abnormal blood lipids.

Clinical trial of treatment for ulcerative colitis
17 Aug 2021

USC Clinical Trials is continuing early-phase research into an investigational treatment that aims to improve the lives of those with mild to moderate ulcerative colitis by reducing inflammation and improving the gut’s healing ability

Contact: media@usc.edu.au

Name Position Email Phone
Janelle Kirkland Media Manager (Acting) jkirklan@usc.edu.au +61 7 5459 4553
Clare McKay Media Relations Coordinator cmckay@usc.edu.au +61 7 5456 5669

Search results for Recent news